Last reviewed 2026-04-23 · How we verify

Placebo for Naftopidil

A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.

A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in phase 3 trial of naftopidil (likely lower urinary tract symptoms or benign prostatic hyperplasia, based on naftopidil's known indication).

At a glance

Mechanism of action

Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. They allow researchers to distinguish between the therapeutic effects of the investigational drug (naftopidil in this case) and effects due to patient expectation or natural disease progression. The placebo arm is essential for demonstrating that any observed clinical benefit is attributable to the active drug rather than placebo response.

Approved indications

• Control arm in phase 3 trial of naftopidil (likely lower urinary tract symptoms or benign prostatic hyperplasia, based on naftopidil's known indication)

Common side effects

No common side effects on file.

Key clinical trials

• Medical Expulsive Therapy for Ureter Stone Using Naftopidil (PHASE3)
• The Effect of Naftopidil for the Double-J Stent Discomfort (PHASE3)
• Naftopidil 75mg for Improving Clearance of Urinary Stones (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo for Naftopidil CI brief — competitive landscape report
• Placebo for Naftopidil updates RSS · CI watch RSS
• Seoul National University Hospital portfolio CI